Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 204

Similar articles for PubMed (Select 12679522)

1.

Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions.

Williams JA, Guicherit OM, Zaharian BI, Xu Y, Chai L, Wichterle H, Kon C, Gatchalian C, Porter JA, Rubin LL, Wang FY.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4616-21. Epub 2003 Apr 4. Erratum in: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8607.

2.

FRET-based cholesterolysis assay identifies a novel hedgehog inhibitor.

Owen TS, Ngoje G, Lageman TJ, Bordeau BM, Belfort M, Callahan BP.

Anal Biochem. 2015 Jun 18. pii: S0003-2697(15)00314-0. doi: 10.1016/j.ab.2015.06.021. [Epub ahead of print]

PMID:
26095399
3.

Crosstalk between Desmoglein 2 and Patched 1 accelerates chemical-induced skin tumorigenesis.

Brennan-Crispi DM, Hossain C, Sahu J, Brady M, Riobo NA, Mahoney MG.

Oncotarget. 2015 Apr 20;6(11):8593-605.

4.

Hedgehog signaling in basal cell carcinoma.

Otsuka A, Levesque MP, Dummer R, Kabashima K.

J Dermatol Sci. 2015 May;78(2):95-100. doi: 10.1016/j.jdermsci.2015.02.007. Epub 2015 Feb 23. Review.

PMID:
25766766
5.

Basal cell carcinoma, Hedgehog signaling, and targeted therapeutics: the long and winding road.

Wong SY, Dlugosz AA.

J Invest Dermatol. 2014 Oct 10;134(e1):E18-22. doi: 10.1038/skinbio.2014.4. Review. No abstract available.

PMID:
25302468
6.

Vismodegib in the treatment of advanced BCC.

O'Kane GM, Lyons T, McDonald I, Mulligan N, Moloney FJ, Murray D, Kelly CM.

Ir Med J. 2014 Jul-Aug;107(7):215-6.

PMID:
25226719
7.

Interaction of hedgehog and vitamin D signaling pathways in basal cell carcinomas.

Albert B, Hahn H.

Adv Exp Med Biol. 2014;810:329-41. Review.

PMID:
25207374
8.

Zfx facilitates tumorigenesis caused by activation of the Hedgehog pathway.

Palmer CJ, Galan-Caridad JM, Weisberg SP, Lei L, Esquilin JM, Croft GF, Wainwright B, Canoll P, Owens DM, Reizis B.

Cancer Res. 2014 Oct 15;74(20):5914-24. doi: 10.1158/0008-5472.CAN-14-0834. Epub 2014 Aug 27.

PMID:
25164012
9.

Precision medicine and precision therapeutics: hedgehog signaling pathway, basal cell carcinoma and beyond.

Mohan SV, Chang AL.

Semin Cutan Med Surg. 2014 Jun;33(2):68-71. Review.

PMID:
25085664
10.

Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.

Lyons TG, O'Kane GM, Kelly CM.

Expert Opin Drug Saf. 2014 Aug;13(8):1125-32. doi: 10.1517/14740338.2014.939952. Review.

PMID:
25033383
11.

Discovery and preclinical development of vismodegib.

Gould SE, Low JA, Marsters JC Jr, Robarge K, Rubin LL, de Sauvage FJ, Sutherlin DP, Wong H, Yauch RL.

Expert Opin Drug Discov. 2014 Aug;9(8):969-84. doi: 10.1517/17460441.2014.920816. Epub 2014 May 23. Review.

PMID:
24857041
12.

Emerging drugs and combination strategies for basal cell carcinoma.

Dreier J, Dummer R, Felderer L, Nägeli M, Gobbi S, Kunstfeld R.

Expert Opin Emerg Drugs. 2014 Sep;19(3):353-65. doi: 10.1517/14728214.2014.914171. Epub 2014 Apr 29. Review.

PMID:
24773312
13.

Vismodegib.

Meiss F, Zeiser R.

Recent Results Cancer Res. 2014;201:405-17. doi: 10.1007/978-3-642-54490-3_25. Review.

PMID:
24756807
14.

Depletion of cutaneous macrophages and dendritic cells promotes growth of basal cell carcinoma in mice.

König S, Nitzki F, Uhmann A, Dittmann K, Theiss-Suennemann J, Herrmann M, Reichardt HM, Schwendener R, Pukrop T, Schulz-Schaeffer W, Hahn H.

PLoS One. 2014 Apr 1;9(4):e93555. doi: 10.1371/journal.pone.0093555. eCollection 2014.

15.

Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.

Ruiz Salas V, Alegre M, Garcés JR, Puig L.

Expert Rev Anticancer Ther. 2014 Jun;14(6):741-9. doi: 10.1586/14737140.2014.895326. Epub 2014 Mar 10. Review.

PMID:
24611655
16.
17.

Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.

Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, Fu T, Gilliam A, Molgo M, Beachy PA, Tang JY.

J Clin Oncol. 2014 Mar 10;32(8):745-51. doi: 10.1200/JCO.2013.49.9525. Epub 2014 Feb 3.

18.

Smoothened inhibitors in the treatment of advanced basal cell carcinomas.

Kunstfeld R.

Curr Opin Oncol. 2014 Mar;26(2):184-95. doi: 10.1097/CCO.0000000000000058. Review.

PMID:
24469022
19.

Role of CRD-BP in the growth of human basal cell carcinoma cells.

Noubissi FK, Kim T, Kawahara TN, Aughenbaugh WD, Berg E, Longley BJ, Athar M, Spiegelman VS.

J Invest Dermatol. 2014 Jun;134(6):1718-24. doi: 10.1038/jid.2014.17. Epub 2014 Jan 27.

20.

Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma.

Aditya S, Rattan A.

Indian Dermatol Online J. 2013 Oct;4(4):365-8. doi: 10.4103/2229-5178.120685.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk